0001104659-22-027293.txt : 20220225 0001104659-22-027293.hdr.sgml : 20220225 20220225160543 ACCESSION NUMBER: 0001104659-22-027293 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220222 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220225 DATE AS OF CHANGE: 20220225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellectar Biosciences, Inc. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36598 FILM NUMBER: 22679887 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (608) 441-8120 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: NOVELOS THERAPEUTICS, INC. DATE OF NAME CHANGE: 20050617 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 8-K 1 tm227716d1_8k.htm FORM 8-K
0001279704 false 0001279704 2022-02-22 2022-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 22, 2022

 

 

Cellectar Biosciences, Inc.

(Exact name of Registrant as Specified in its Charter)

 

 

Delaware  1-36598  04-3321804
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS. Employer
Identification No.)

 

100 Campus Drive, Florham Park, NJ, 07932

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (608) 441-8120

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Common Stock, par value $0.00001 per share   CLRB   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b)

 

On February 22, 2022, Dov Elefant, the Chief Financial Officer of Cellectar Biosciences, Inc. (the “Company”), resigned from his office effective February 22, 2022.

 

(c)

 

On February 22, 2022, Chad Kolean, age 57, rejoined the Company as its Chief Financial Officer. Mr. Kolean served as the Company’s Chief Financial Officer from 2014 to 2017. From 2017 to 2019, Mr. Kolean was the Chief Financial Officer of Titan Spine, Inc., a developer of titanium interbody implants, and from 2019 to 2022, Mr. Kolean was the Chief Financial Officer of VIVEX Biologics, Inc., a developer of biologic and regenerative health therapies. Mr. Kolean received his Bachelor of Arts from Hope College.

 

In connection with his employment, Mr. Kolean entered into an employment agreement and an indemnification agreement with the Company. Pursuant to his employment agreement, Mr. Kolean will receive an annual base salary of $340,000 and will be eligible to receive an annual performance bonus with a target amount equal to 40% of his base salary. In the event of a dismissal without cause, or resignation by Mr. Kolean for good reason, Mr. Kolean will be entitled to nine months of severance. In the event of dismissal without cause, or resignation by Mr. Kolean for good reason, within the twelve months following a change in control, Mr. Kolean will be entitled to eighteen months of severance.

 

Additionally, Mr. Kolean was granted an option to purchase 150,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on February 22, 2022. The shares subject to the option award vest annually over three years such that 1/3 of the number of shares granted become exercisable on each anniversary of the grant date, so that the option to purchase shares will be fully vested on the third anniversary of the grant date. Mr. Kolean will be eligible for annual equity awards under the Company’s Amended and Restated 2021 Stock Incentive Plan.

 

Mr. Kolean has no family relationships with any director or executive officer of the Company. There are no arrangements or understandings between Mr. Kolean and any other persons pursuant to which he was selected as an officer of the Company, and there are no transactions in which Mr. Kolean has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

On February 22, 2022, Jarrod Longcor, age 48, was promoted to the Company’s Chief Operating Officer. Mr. Longcor has been serving as the Company’s Chief Business Officer and Senior Vice President of Operations since 2017.

 

Mr. Longcor has no family relationships with any director or executive officer of the Company. There are no arrangements or understandings between Mr. Longcor and any other persons pursuant to which he was selected as an officer of the Company, and there are no transactions in which Mr. Longcor has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Number   Title
10.1   Employment Agreement between the Company and Chad Kolean, dated February 23, 2022
99.1   Press release, dated February 23, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CELLECTAR BIOSCIENCES, INC.
     
Date: February 25, 2022 By: /s/ Chad Kolean
  Name: Chad Kolean
  Title: Chief Financial Officer

 

 

 

EX-10.1 2 tm227716d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of February 23, 2022, between CELLECTAR BIOSCIENCES, INC., a Delaware corporation (the "Company"), and Chad Kolean ("Executive").

 

RECITALS

 

The Company and Executive desire to enter into this Agreement to document the terms and conditions of Executive's employment by the Company. The parties hereto agree as follows:

 

1.            Employment. The Company shall employ Executive, and Executive hereby agrees to employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on or about February 22, 2022 and ending as provided in Section 4 hereof (the “Employment Period”).

 

2.Position and Duties.

 

(a)            During the Employment Period, Executive will serve as the Vice President and Chief Financial Officer of the Company. Executive will have the normal duties, responsibilities and authority of his role, subject to the overall direction and authority of the Board of Directors of the Company (the “Board”) and the Chief Executive Officer.

 

(b)            During the Employment Period, except as otherwise determined by the Board, Executive will report to the Chief Executive Officer, and will devote his full business time and attention (except for permitted vacation periods and reasonable periods of illness or other incapacity) to the business and affairs of the Company. During the Employment Period, Executive shall not serve as an officer or director of, or otherwise perform services for compensation for, any other entity without the prior written consent of the Board (which shall not be unreasonably withheld or delayed); provided that Executive may serve as an officer or director of or otherwise participate in purely educational, welfare, social, religious, recreational and civic organizations so long as such activities do not interfere with Executive's employment.

 

(c)            For purposes of this Agreement, the term "Company" shall include all of the Company's Subsidiaries. The term "Subsidiaries" shall mean any corporation or other entity of which the securities or other ownership interests having the voting power to elect a majority of the board of directors or other governing body are, at the time of determination, owned by the Company, directly or through one or more Subsidiaries.

 

3.Compensation and Benefits.

 

(a)            Compensation.

 

(i)      Base Salary.      During the Employment Period, Executive's base salary will be three hundred fifteen thousand dollars ($340,000) per annum (as may be adjusted from time to time by the Board, the "Base Salary"), which salary will be payable by the Company in regular installments in accordance with the Company's general payroll practices (in effect from time to time). Executive's Base Salary for any partial year will be prorated based upon the number of days elapsed in such year.

 

1

 

 

(ii)            Bonus. During the Employment Period, Executive will be eligible to earn an annual cash bonus each calendar year, under the terms and conditions of the Company's annual incentive compensation plan for which Executive's initial target shall be forty percent (40%) of Base Salary (the “Annual Bonus”).

 

(iii)            Equity Award. The Company shall grant to Executive an option to purchase one hundred-fifty thousand (150,000) shares of the Company’s Common Stock (the “Option Grant”). The exercise price per share shall be equal to the closing market price on the date of grant. The Option shall vest in three equal annual installments beginning on the first anniversary of the date of grant. The Option shall be evidenced by an option agreement. Executive shall be eligible to receive periodic future stock option grants at the discretion of the Board.

 

(b)Benefits.

 

(i)            During the Employment Period, Executive will be entitled to participate in all of the Company's employee benefit programs for which senior executive employees of the Company are generally eligible in accordance with the terms and conditions of such programs as the same may be modified from time to time.

 

(ii)            In addition to the benefits described in Section 3(b)(i) above, during the Employment Period, Executive will also be entitled to the following (without duplication):

 

(A)            Vacation. Four weeks of paid vacation each calendar year, which if not taken during any year may not be carried forward to subsequent calendar year(s) or otherwise paid; and

 

(B)            Personal Days. Four paid personal days each calendar year, which if not taken during any year may not be carried forward to subsequent calendar year(s) or otherwise paid; and

 

(C)            Business Expenses. Reimbursement for all reasonable business expenses incurred by Executive in the course of performing his duties and responsibilities under this Agreement, and that are excludable from gross income, with respect to travel, entertainment and other business expenses, subject to the Company's requirements with respect to reporting and documentation of such expenses.

 

(c)            Withholding. All amounts payable to Executive as compensation hereunder shall be subject to all required and customary withholding by the Company.

 

4.Termination and Obligations of the Company Upon Termination.

 

(a)            At-Will Employment. Executive’s employment is at-will and shall be of no specific period. Executive is free to resign at any time, for any reason or no reason, as Executive deems appropriate. Subject to this Section 4, the Company has a similar right to terminate Executive employment at any time, with or without Cause (as defined below).

 

(b)            Death. If Executive's employment is terminated due to Executive's death, the Company will pay to Executive's estate Executive's (i) Base Salary through the date of termination to the extent not theretofore paid, any accrued vacation pay to the extent not theretofore paid and any reimbursement of business expenses as described in Section 3(b)(ii)(C) above (together, the "Accrued Obligations") and (ii) the bonus described in Section 3(a)(ii) above for the calendar year in which such termination occurs if Executive would have otherwise been entitled to receive such bonus had his employment not been terminated (provided that if the date of such termination occurs prior to the last day of the calendar year in respect of which such bonus is awarded, then such bonus will be prorated upon the number of days elapsed prior to Executive's date of termination). Any such bonus amount payable under this Section 4(b) will be payable at such time as such amount would have been payable had Executive's employment not been terminated.

 

2

 

 

(c)            Disability. If Executive's employment is terminated either by Executive or the Company due to Executive's Disability, Executive will be entitled to receive (i) his Accrued Obligations, (ii) such benefits as are available to Executive under the Company's long-term disability insurance plans (if any) as in effect on the date of termination, (iii) continuation of Company provided health insurance at the Company's cost during the COBRA continuation period, and (iv) the bonus described in Section 3(a)(ii) above for the calendar year in which such termination occurs if Executive would have otherwise been entitled to receive such bonus had his employment not been terminated (provided that if the date of such termination occurs prior to the last day of the calendar year in respect of which such bonus is awarded, then such bonus will be prorated upon the number of days elapsed prior to Executive's date of termination). Any such bonus amount payable under this Section 4(c) will be payable at such time as such amount would have been payable had Executive's employment not been terminated. “Disability” means any physical or mental condition of Executive that (i) results in a qualification for benefits under the Company's long-term disability insurance plans (referred to above) or (ii) in the good faith judgment of the Board, based upon the receipt of competent medical advice, results in the inability of Executive to perform his services under this Agreement and such incapacity will likely continue for a period of at least 180 consecutive days or at least 180 days in any 365 consecutive day period.

 

(d)            Resignation or Termination for Cause. If Executive's employment is terminated due to Executive's resignation without Good Reason (as defined below) or a termination by the Company for Cause, Executive will be entitled to receive his Accrued Obligations.

 

(e)            Termination by the Company Without Cause, or by Executive for Good Reason. If Executive's employment is terminated by (i) the Company without Cause, or (ii) by Executive for "Good Reason," Executive will be entitled to receive (A) his Accrued Obligations, (B) a cash severance payment equal to seventy-five percent (75%) of Executive's then applicable Base Salary, payable in regular installments in accordance with the Company's general payroll practices (in effect from time to time) beginning on the first pay date following the date of termination and ending on the ninth monthly anniversary date of the first pay date provided, however, that if Executive is terminated by (i) the Company without Cause, or (ii) by Executive for "Good Reason," within 12 months after a Change in Control, Executive will be entitled to receive an increased severance payment equal to one hundred-fifty percent (150%) of Executive’s then applicable Base Salary and Annual Bonus, each payable in eighteen (18) monthly installments pursuant to the terms of this Section 4(e)(B), and (C) addition of the cost of Company-provided health insurance to each severance payment made in accordance with Section 4(e)(B) above (for 9 or 18 months as applicable). In addition to the foregoing, the Company shall provide to Executive, for a period of up to nine (9) months following the date of termination of employment with the Company, outplacement services, including, but not limited to: instruction and counseling to assess and develop job goals and interviewing, networking and negotiating skills; assistance with resume preparation and initiation of a job search; secretarial support, and the use of private offices at the outplacement firm's premises. Executive and the Company shall agree upon the outplacement services provider, and the aggregate cost of such services under this Section 4(e) shall not exceed Seventy Five Hundred Dollars ($7,500).

 

3

 

 

As a condition to the Company's obligations to make the payments described in this Section 4(e), the Company and Executive will execute and deliver within 30 days after the date of termination of employment a general mutual release in the form reasonably required by the Company. Notwithstanding anything in this Agreement to the contrary, the Company will have no obligation to pay any amounts payable under this Section 4(e) during such times as Executive is in breach of Sections 5, 6, or 7 hereof.

 

(f)            Other. Except as otherwise expressly provided herein, all of Executive's rights to salary, bonuses, employee benefits and other compensation hereunder which would have accrued or become payable after the termination or expiration of the Employment Period shall cease upon such termination or expiration, other than those expressly required under applicable law.

 

(g)            Definition of "Cause.” For purposes of this Agreement, "Cause" shall mean:

 

(l)            the commission by Executive of a (i) felony or (ii) to the extent it compromises the best interests of the Company or renders Executive unfit or unable to perform his services and duties hereunder, any other criminal act (excluding any such acts involving the operation of a motor vehicle);

 

(2)            the commission by Executive of any act or any omission to act by Executive involving fraud, dishonesty or disloyalty with respect to the Company or any of its customers or suppliers;

 

(3)            the continued failure by Executive to perform substantially his duties to the Company (other than any such failure resulting from Executive's Disability) after written notice thereof (specifying the particulars thereof in reasonable detail and requirements for remediation) and a reasonable opportunity to be heard and cure such failure, if cure is possible under the circumstances, are given to Executive by the Board (it being agreed that such opportunity to be heard and cure period shall not cumulatively exceed thirty (30) consecutive days from the date written notice of such failure to perform is delivered by Executive); or

 

(4)a breach by Executive of Sections 5, 6, or 7 hereof.

 

Notwithstanding the foregoing, immediately following a "Change in Control" of the Company, the definition of Cause shall exclude Subsection 4(g)(3) above.

 

(h)            Definition of Good Reason. A termination by Executive for "Good Reason" means Executive's resignation from employment by the Company, after any of the following and not later than thirty (30) days following the expiration of the Cure Period (defined below):

 

(1)            a decrease of ten percent (10%) or more in Executive's Base Salary;

 

(2)            a material diminution in Executive's authority, duties, or responsibilities;

 

(3)            a requirement that Executive relocate his primary office to a location more than thirty (30) miles away from his current location; or

 

4

 

 

(4)            any other action or inaction that constitutes a material breach by the Company of this Agreement.

 

No occurrence shall constitute a basis for a termination for "Good Reason" unless Executive notifies the Company, in writing, within thirty (30) days after such occurrence that Executive considers such occurrence to be a basis for a termination with "Good Reason" and, the Company fails to cure such occurrence within (30) days following receipt of such notice. The Company and Executive intend that a resignation by Executive for Good Reason, as defined above, constitutes an involuntary separation from service within the meaning of Section 409A of the Internal Revenue Code (the "Code").

 

(i)            Definition of Change in Control. For purposes of this Agreement, "Change in Control" shall mean (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any person or group (within the meaning of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder as then in effect) of shares representing more than 50% of the aggregate voting power represented by the issued and outstanding capital stock of the Company entitled to vote in the election of directors, (b) the occupation of a majority of the seats (other than vacant seats) on the Board by persons who were neither (i) nominated by the Board; nor (ii) appointed by directors so nominated, (c) the dissolution or liquidation of the Company, (d) a reorganization, merger, or consolidation of the Company with one or more entities as a result of which the holders of the Company's outstanding equity securities prior to such transaction do not hold equity securities representing a majority of the voting power of the surviving entity, or (e) the sale of all or substantially all of the Company's assets.

 

5.            Confidential Information and Trade Secrets.

 

(a)            “Confidential Information” means information (to the extent it is not a Trade Secret), whether oral, written, recorded, magnetically or electronically or otherwise stored and whether originated by Executive or otherwise coming into the possession or knowledge of Executive, which is possessed by or developed for the Company and which relates to the Company’s existing or potential business, which information is not reasonably ascertainable by the Company’s competitors or by the general public through lawful means, and which information the Company treats as confidential, including but not limited to information regarding the Company’s products or services, specifications, designs, processes, business affairs, business plans, strategies, finances, computer programs, research, customer development, planning, purchasing, finance, marketing, customer relations and customer information, and other information received by the Company from others which the Company has an obligation to treat as confidential. “Trade Secret” means a trade secret as that term is defined under Wis. Stat. §134.90.

 

(b)            Confidentiality Obligations. During the Employment Period and for a period of two (2) years after the termination of Executive’s employment with the Company, regardless of the reason for such termination, Executive shall not use or disclose any of the Company’s Confidential Information. Additionally, during and after termination of employment with the Company, Executive shall not use or disclose the Company’s Trade Secrets so long as they remain Trade Secrets.

 

6.            Intellectual Property; Inventions and Patents. Executive acknowledges and agrees that all inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports and all similar or related information (whether or not patentable) which relate to the Company's or any of its Subsidiaries' actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by Executive while employed by the Company ("Work Product") belong to the Company or such Subsidiary. Executive will promptly disclose such Work Product to the Board and perform all actions reasonably requested by the Board (whether during or after the Employment Period) to establish and confirm such ownership (including, without limitation, assignments, consents, powers of attorney and other instruments).

 

5

 

 

7.Noncompetition; Non-Solicitation.

 

(a)            Noncompetition. Executive acknowledges that in the course of his employment with the Company he shall become familiar with the Company's trade secrets and with other Confidential Information concerning the Company and its Subsidiaries and that his services shall be of special and unique value to the Company and its Subsidiaries. Therefore, Executive agrees that, during the period of Executive's employment with the Company and for period of nine (9) consecutive months immediately following the date of Executive's termination of employment by the Company (the "Noncompete Period"), he shall not, without prior written approval by the Board, directly or indirectly participate in any country in which the Company is doing business at the time of Executive's termination of employment with the Company in any business competing with the businesses of the Company or its Subsidiaries conducted during the Employment Period (collectively, the "Business"), either as a partner, proprietor, shareholder, officer, director, agent, employee, consultant or otherwise. Executive agrees and acknowledges that the potential harm to the Company of its non-enforcement outweighs any harm to Executive of its enforcement by injunction or otherwise. Executive further acknowledges and agrees that each and every restraint imposed by this Agreement is reasonable with respect to subject matter, time period and geographical area. Nothing herein shall prohibit Executive from being a passive owner of not more than five percent (5%) of the outstanding securities of any publicly traded company engaged in the Business, so long as Executive has no active participation in the Business of such company, unless otherwise approved by the Board.

 

(b)            Non-Solicitation. During the Noncompete Period, Executive shall not directly or indirectly (i) induce or attempt to induce any employee of the Company or any Subsidiary to leave the employ of the Company or such Subsidiary (other than through general advertisements for employment not directed at employees of the Company or any of its Subsidiaries), (ii) solicit to hire any person who was an employee of the Company or any Subsidiary at any time during the six (6) months preceding the termination of the Employment Period (other than through general advertisements for employment not directed at employees of the Company or any of its Subsidiaries) or (iii) solicit or attempt to solicit for the purpose of engaging in any business in which the Company was engaged at the time of Executive's termination of employment and in which the Company was still engaged at the time of Executive's solicitation, any customer who was a customer of the Company during the last twelve (12) months of Executive's employment with the Company.

 

(c)            Enforcement. If at the time of enforcement of Sections 5, 6, or 7 of this Agreement a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum period, scope or geographical area reasonable under such circumstances shall be substituted for the stated period, scope, or area. Because Executive's services are unique and because Executive has access to Confidential Information and Work Product, the parties hereto agree that money damages would not be an adequate remedy for any breach of this Agreement. Therefore, in the event a breach or threatened breach of this Agreement, the Company or its successors or assigns may, in addition to other rights and remedies existing in their favor, apply to any court of competent jurisdiction for specific performance and/or injunctive or other relief in order to enforce, or prevent any violations of, the provisions hereof (without posting a bond or other security). In addition, in the event of an alleged breach or violation by Executive of Section 7(a) or 7(b), the Noncompete Period will be tolled during the pendency of any proceeding (including any arbitration) over such breach or violation, provided that such proceeding was initiated during the Noncompete Period. Executive agrees that the restrictions contained in Sections 5, 6, and 7 are reasonable.

 

6

 

 

8.Section 280G.

 

(a)            If any of the payments or benefits received or to be received by Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or Executive's termination of employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement, or otherwise) (all such payments collectively referred to herein as the 280G Payments) constitute “parachute payments” within the meaning of Section 280G of the Code and would, but for this Section 8, be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then prior to making the 280G Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to Executive of the 280G Payments after payment of the Excise Tax to (ii) the Net Benefit to Executive if the 280G Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will the 280G Payments be reduced to the minimum extent necessary to ensure that no portion of the 280G Payments is subject to the Excise Tax. “Net Benefit” shall mean the present value of the 280G Payments net of all federal, state, local, foreign income, employment, and excise taxes. Any reduction made pursuant to this Section 8 shall be made in a manner determined by the Company that is consistent with the requirements of Section 409A.

 

(b)            All calculations and determinations under this Section 8 shall be made by an independent accounting firm or independent tax counsel appointed by the Company (the “Tax Counsel”) whose determinations shall be conclusive and binding on the Company and Executive for all purposes. For purposes of making the calculations and determinations required by this Section 8, the Tax Counsel may rely on reasonable, good faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code. The Company and Executive shall furnish the Tax Counsel with such information and documents as the Tax Counsel may reasonably request in order to make its determinations under this Section 8. The Company shall bear all costs the Tax Counsel may reasonably incur in connection with its services.

 

9.Section 409A.

 

(a)            General Compliance. This Agreement is intended to comply with Section 409A or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. For purposes of Section 409A, each installment payment provided under this Agreement shall be treated as a separate payment. Any payments to be made under this Agreement upon a termination of employment shall only be made upon a "separation from service" under Section 409A. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by Executive on account of non-compliance with Section 409A.

 

(b)            Specified Employee. Notwithstanding any other provision of this Agreement, if any payment or benefit provided to Executive in connection with his termination of employment is determined to constitute "nonqualified deferred compensation" within the meaning of Section 409A and Executive is determined to be a "specified employee" as defined in Section 409A(a)(2)(b)(i), then such payment or benefit shall not be paid until the first payroll date to occur following the six-month anniversary of the Termination Date or, if earlier, on Executive's death (the "Specified Employee Payment Date"). The aggregate of any payments that would otherwise have been paid before the Specified Employee Payment Date shall be paid to Executive in a lump sum on the Specified Employee Payment Date and thereafter, any remaining payments shall be paid without delay in accordance with their original schedule.

 

7

 

 

(c)            Reimbursements. To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement shall be provided in accordance with the following:

 

(i)            the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;

 

(ii)            any reimbursement of an eligible expense shall be paid to Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and

 

(iii)            any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.

 

(d)            Tax Gross-ups. Any tax gross-up payments provided under this Agreement shall be paid to Executive on or before December 31 of the calendar year immediately following the calendar year in which Executive remits the related taxes.

 

10.Miscellaneous.

 

(a)            Survival. Except as otherwise provided in this Agreement, Sections 4 through 10, inclusive, shall survive and continue in full force in accordance with their terms notwithstanding the expiration or termination of the Employment Period.

 

(b)            Notices. Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, sent by reputable overnight courier service or mailed by first class mail, return receipt requested, to the recipient at the address below indicated:

 

  Notices to Executive:
   
  Chad Kolean
  W6485 County Rd. H
  New Glarus, WI 53574
   
  Notices to the Company:
   
  Cellectar Biosciences, Inc.
  100 Campus Drive
  Florham Park, New Jersey 07932
  Attention: Board of Directors
    Chief Executive Officer and Secretary

 

or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party. Any notice under this Agreement shall be deemed to have been given when so delivered, sent or mailed.

 

8

 

 

(c)            Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any action in any other jurisdiction, but this Agreement shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

 

(d)            Complete Agreement. This Agreement, those documents expressly referred to herein and other documents of even date herewith embody the complete agreement and understanding among the parties and supersede and preempt any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way.

 

(e)            No Strict Construction. The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.

 

(f)            Counterparts. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.

 

(g)            Successors and Assigns. This Agreement shall bind and inure to the benefit of and be enforceable by Executive, the Company and their respective heirs, successors and assigns, except that Executive may not assign his rights or delegate his duties or obligations hereunder without the prior written consent of the Company.

 

The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “company” shall mean the Company as herein before defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise.

 

(h)            Choice of Law. All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement and the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware. Subject to Section 10(i) below, each party hereby expressly and irrevocably agrees that any case or controversy related to this Agreement must be conducted in the State of Delaware. Each party hereby irrevocably consents to personal jurisdiction in such court and to accept service of process in accordance with the provisions of the laws of the State of Delaware. Executive hereby waives any and all right to trial by jury in any action or proceeding related to this Agreement.

 

9

 

 

(i)            Dispute Resolution. Because disputes arising in connection with complex agreements are most quickly and economically resolved by an experienced and expert person, the parties agree that claims relating to an alleged breach of this Agreement (excluding claims arising under Sections 5, 6, and/or 7) shall be resolved by binding arbitration with a single arbitrator before the American Arbitration Association in Delaware, pursuant to the then-applicable rules of the American Arbitration Association. If Executive is determined in such arbitration to be successful in asserting his rights, Executive shall be entitled to reimbursement of all legal fees reasonably incurred in asserting Executive's rights under the Agreement.

 

(j)            Amendment and Waiver. The provisions of this Agreement may be amended or waived only with the prior written consent of the Company (as approved by the Board) and Executive, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement (including, without limitation, the Company's right to terminate the Employment Period for Cause) shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.

 

(k)            Insurance. The Company may, at its discretion, apply for and procure in its own name and for its own benefit life and/or disability insurance on Executive in any amount or amounts considered advisable. Executive agrees to cooperate in any medical or other examination, supply any information and execute and deliver any applications or other instruments in writing as may be reasonably necessary to obtain and constitute such insurance.

 

(l)            Executive's Cooperation. During the Employment Period and thereafter, Executive shall cooperate with the Company and its Subsidiaries in any internal investigation, any administrative, regulatory or judicial investigation or proceeding or any dispute with a third party as reasonably requested by the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company's request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are or may come into Executive's possession, all at times and on schedules that are reasonably consistent with Executive's other permitted activities and commitments).

 

10

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

 

  CELLECTAR BIOSCIENCES, INC.
   
  By: /s/ James Caruso       
    James V. Caruso
   
  Its: President and Chief Executive Officer
   
   
  EXECUTIVE
   
   
  /s/ Chad Kolean
  Chad Kolean

 

11

 

EX-99.1 3 tm227716d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

Cellectar Biosciences Announces Executive Leadership Changes

 

Names Mr. Chad Kolean as Chief Financial Officer

 

Promotes Mr. Jarrod Longcor to Chief Operating Officer

 

 

FLORHAM PARK, N.J., February 23, 2022 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced it has named Mr. Chad Kolean as Chief Financial Officer and promoted Mr. Jarrod Longcor to the role of Chief Operating Officer. Mr. Kolean, a seasoned thirty-year industry veteran, will replace Dov Elefant, who is leaving to pursue other opportunities.

 

“It is with great enthusiasm that I congratulate Jarrod for his promotion to Chief Operating Officer and warmly welcome Chad back to the Cellectar family,” said James Caruso, CEO of Cellectar. “Chad is returning to us after further strengthening and broadening his impressive business acumen having served as CFO to two commercial companies, one of which was sold for an attractive premium. We are very pleased to have him join us once again, with his deep understanding of the company and broad industry knowledge. We appreciate Dov’s contributions and wish him well.”

 

Mr. Caruso continued, “Jarrod’s promotion to Chief Operating Officer is well deserved and acknowledges the broad value he brings to the team beyond his previous role as Chief Business Officer. His added responsibilities will include overseeing our growth as we continue to enhance our capabilities across the organization, where we have added to our manufacturing and regulatory functions and have planned strategic commercial hires in preparation for a potential NDA filing in Waldenstrom’s macroglobulinemia (WM). We look forward to announcing the results of the planned prespecified safety & efficacy assessment in the near term and completion of our pivotal trial in WM. We remain committed to unlocking the potential of iopofosine I-131 in and beyond WM as we progress our ongoing trials.”

 

Mr. Chad Kolean returns to Cellectar after having served as Chief Financial Officer to both Vivex Biologics, a regenerative medicine company and Titan Spine, a spinal implant med-tech company sold to Medtronic. Mr. Kolean also served as Chief Financial Officer and Treasurer for Pioneer Surgical Technology, a biologic and orthopedic implant company through its merger with RTI Surgical. Early in his career, Mr. Kolean held leadership positions of increasing responsibility at multinational companies and those within the healthcare space including Tomotherapy, Inc., Metavante Corporation, Snap On, Inc., Herman Miller, Inc., Kaydon Corporation, and Arthur Andersen, LLP. Mr. Kolean earned his Bachelor of Arts in Business Administration and Finance from Hope College and graduated Magna Cum Laude.

 

Mr. Jarrod Longcor will add the new role of Chief Operating Officer to his Chief Business Officer responsibilities. He will lead and provide strategic oversight of the company’s key functional areas to ensure operational excellence as Cellectar progresses through its clinical development programs and advances towards commercialization. Mr. Longcor has been with the company for 6 years as both a consultant and Chief Business Officer.

 

 

 

Grant of Inducement Option

 

In connection with his hiring, Cellectar has granted to Mr. Chad Kolean, effective as of his first day of employment with Cellectar, an option to purchase 150,000 shares of Cellectar’s common stock at an exercise price per share equal to the closing price of Cellectar’s common stock on the grant date as reported by Nasdaq. This grant was approved by the Compensation Committee of Cellectar’s Board of Directors and made as an inducement material to Mr. Chad Kolean entering into employment with Cellectar as contemplated by Nasdaq Listing Rule 5635(c)(4).

 

The stock option, which has a 10-year term, vests and becomes exercisable in three equal annual installments beginning on the first anniversary from the date of Mr. Chad Kolean’s first day of employment.

 

Cellectar provides this information in accordance with Nasdaq Listing Rule 5635(c)(4).

 

About Cellectar Biosciences, Inc.

 

Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

 

The company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The company is currently investigating iopofosine in a global, pivotal expansion cohort in relapsed or refractory WM patients who have received at least two prior lines of therapy, including those who have failed or had a suboptimal response to Bruton tyrosine kinase inhibitors. The WM cohort will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval. The company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.

 

The Phase 1 pediatric study is an open-label, sequential-group, dose-escalation study to evaluate the safety and tolerability of iopofosine in children and adolescents with relapsed or refractory cancers, including malignant brain tumors, neuroblastoma, sarcomas, and lymphomas (including Hodgkin’s lymphoma). The Phase 1 study is being conducted internationally at seven leading pediatric cancer centers.

 

For more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

 

 

 

Forward-Looking Statement Disclaimer

 

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020 and our Form 10-Q for the quarter ended September 30, 2021. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

 

Contacts

 

Investors:

 

Monique Kosse

Managing Director

LifeSci Advisors

212-915-3820

monique@lifesciadvisors.com

 

 

 

Source: Cellectar Biosciences

 

 

EX-101.SCH 4 clrb-20220222.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 clrb-20220222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 clrb-20220222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm227716d1_ex99-1img001.jpg GRAPHIC begin 644 tm227716d1_ex99-1img001.jpg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end GRAPHIC 8 tm227716d1_ex99-1img002.jpg GRAPHIC begin 644 tm227716d1_ex99-1img002.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 22, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 22, 2022
Entity File Number 1-36598
Entity Registrant Name Cellectar Biosciences, Inc.
Entity Central Index Key 0001279704
Entity Tax Identification Number 04-3321804
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Campus Drive
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code 608
Local Phone Number 441-8120
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol CLRB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 tm227716d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001279704 2022-02-22 2022-02-22 iso4217:USD shares iso4217:USD shares 0001279704 false 8-K 2022-02-22 Cellectar Biosciences, Inc. DE 1-36598 04-3321804 100 Campus Drive Florham Park NJ 07932 608 441-8120 false false false false Common Stock, par value $0.00001 per share CLRB NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cellectar.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm227716d1_8k.htm clrb-20220222.xsd clrb-20220222_lab.xml clrb-20220222_pre.xml tm227716d1_ex10-1.htm tm227716d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm227716d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm227716d1_8k.htm" ] }, "labelLink": { "local": [ "clrb-20220222_lab.xml" ] }, "presentationLink": { "local": [ "clrb-20220222_pre.xml" ] }, "schema": { "local": [ "clrb-20220222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CLRB", "nsuri": "http://cellectar.com/20220222", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm227716d1_8k.htm", "contextRef": "From2022-02-22to2022-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://cellectar.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm227716d1_8k.htm", "contextRef": "From2022-02-22to2022-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://cellectar.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-027293-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-027293-xbrl.zip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end